Philips announces SpectraWAVE acquisition, expanding intravascular imaging portfolio

GlobalData

Wed, December 17, 2025 astatine 5:21 AM CST 2 min read

Philips has agreed to get SpectraWAVE, a Massachusetts-based aesculapian instrumentality institution focused connected technologies to assistance diagnose and usher attraction for patients with coronary artery disease. SpectraWAVE’s exertion specialises successful advancing intravascular imaging and physiological appraisal with AI. This acquisition positions Philips astatine the intersection of diagnostic imaging, cardiovascular health, and AI-driven healthcare. This acquisition volition fortify Philips’ beingness successful the intravascular imaging, physiological assessment, and intravascular ultrasound catheters (IVUS) instrumentality market. Leading information and analytics institution GlobalData predicts that the planetary IVUS marketplace volition spot dependable marketplace worth maturation successful the adjacent future, with a compound yearly maturation complaint of 4% implicit the 2024-2034 period.

Currently Philips leads successful marketplace stock of the planetary (North America, Europe, Asia-Pacific, southbound Central America, and the Middle East and Africa) IVUS market, with 88%. Currently, North America is the largest marketplace for IVUS aesculapian devices, with a marketplace worth of $490m. During the 2024-2034 period, GlobalData forecasts the North American IVUS marketplace to turn successful worth by 6%. Growth successful request for IVUS aesculapian devices stems from the expanding incidence of cardiovascular diseases (CVDs), which are the starring origin of decease globally. Factors that exacerbate the prevalence of CVDs, driving the planetary IVUS market, see ageing populations and a precocious complaint of smoking successful immoderate countries. A worldwide summation successful healthcare spending, arsenic good arsenic the effects of globalisation, volition besides thrust this market. However, the precocious outgo of imaging techniques and a deficiency of bosom speciality hospitals successful immoderate regions volition enactment arsenic barriers to the adoption of IVUS based procedures. Philips’ acquisition of SpectraWAVE volition see the HyperVue Imaging System with AI-supported imaging wrong the coronary arteries and X1-FFR, an AI-enabled angio-based fractional travel reserve (FFR) technology. X1-FFR provides a nonstop provender from angiography systems, which tin beryllium utilized by clinicians successful uncovering the close determination for stent placements and different intervention. Philips’ acquisition of SpectraWAVE volition grow the company’s existent intravascular imaging and physiological appraisal instrumentality portfolio, which includes OmniWire iFR exertion and the Eagle Eye Platinum IVUS. The announcement of Philips' acquisition of SpectraWAVE follows the 2023 501k clearance for SpectraWAVE’s Hypervue Intravascular Imagine System, $50m of Series B backing for SpectraWAVE successful September 2024, and SpectraWAVE gaining Food and Drug Administration clearance for X1-FFR successful October 2025. The coupling of SpectraWAVE’s caller technologies with Philips’ existing catalogue of products and marketplace power volition perchance summation the adoption rates of IVUS-based procedures. The burgeoning exertion of AI successful aesculapian exertion volition supply caller innovations for IVUS technology, arsenic good arsenic for the cardiovascular and diagnostic imaging sectors successful general.